FDA Issues Complete Response Letter to sBLA for Xgeva - MPR
Links shared publicly online about this topic.
- 0total visits
FDA Issues Complete Response Letter to sBLA for Xgeva - MPR
empr.com —
Amgen announced that it received a complete response letter from the FDA for it supplemental Biologics License Application (sBLA) for Xgeva (denosumab) injection for the treatment of men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
View full resource at empr.com
Most Recently Shared on April 27, 2012 at 4:02 pm By:
FDA Issues Complete Response Letter to sBLA for Xgeva #amgen #prostate #oncology http://t.co/9fR1ub9L
FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
jnj.com — “Johnson & Johnson news and information regarding our operations, products, leaders, and our charitable giving.” View full resource at jnj.com
Most Recently Shared on July 22, 2011 at 11:34 pm By:
Marc Monseau Pharma and Health Social Media
$JNJ News Release: #FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI sBLA> http://t.co/GHS7RRI >
Advertisement
